Equities

Dyadic International Inc

DYAI:NAQ

Dyadic International Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.25
  • Today's Change0.06 / 5.04%
  • Shares traded25.91k
  • 1 Year change-34.55%
  • Beta0.7493
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Dyadic International Inc had revenues remain flat at 2.93m, though the company grew net income from a loss of 9.74m to a smaller loss of 6.80m. A reduction in the selling, general and administrative costs as a percentage of sales from 219.14% to 200.67% was a component in the net income growth despite flat revenues.
Gross margin50.01%
Net profit margin-429.07%
Operating margin-443.21%
Return on assets-71.33%
Return on equity-127.38%
Return on investment-87.19%
More ▼

Cash flow in USDView more

In 2023, Dyadic International Inc increased its cash reserves by 12.44%, or 720.76k. Cash Flow from Investing totalled 7.45m, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 6.73m for operations while cash from financing was breakeven.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.1075
Tangible book value per share0.1075
More ▼

Balance sheet in USDView more

Dyadic International Inc appears to have a strong balance sheet with enough cash in the capital structure to pay down 100% of the liabilities.
Current ratio5.39
Quick ratio--
Total debt/total equity1.72
Total debt/total capital0.6324
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.